YTE-001 is under clinical development by Bristar Immunotech Biotechnology and currently in Phase I for Hemophagocytic Lymphohistiocytosis. According to GlobalData, Phase I drugs for Hemophagocytic Lymphohistiocytosis have a 100% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how YTE-001’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

YTE-001 overview

Gene therapy is under development for the treatment of Epstein Barr virus (EBV) infections after hematopoietic stem cell transplantation (HSCT), EBV-associated hemophagocytic lymphohistiocytosis and EBV-positive, refractory nasopharyngeal carcinoma. The therapeutic candidate consists of lentivirus and comprises of genetically engineered allogenic T-cells to express virus specific T-cell receptor (TCR). It is administered through intravenous route. The therapeutic candidate acts by targeting EBV antigen such as LMP1, LMP2 and EBNA1.

Bristar Immunotech Biotechnology overview

Bristar Immunotech Biotechnology (Bristar Immunotech) is a biotechnology company focused on development and commercialization of cellular immunotherapy products for various diseases represented by TCR-T. Huaxia Yingtai is headquartered in Beijing, China.

For a complete picture of YTE-001’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.